UBS Group’s NEVRO CORP. NVRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-123,082
| Closed | -$719K | – | 11200 |
|
|
2025
Q1 | $719K | Sell |
123,082
-48,335
| -28% | -$255K | ﹤0.01% | 5564 |
|
|
2024
Q4 | $638K | Buy |
171,417
+161,836
| +1,689% | +$747K | ﹤0.01% | 5667 |
|
|
2024
Q3 | $53.6K | Sell |
9,581
-4,422
| -32% | -$30.9K | ﹤0.01% | 6773 |
|
|
2024
Q2 | $118K | Sell |
14,003
-25,006
| -64% | -$267K | ﹤0.01% | 6064 |
|
|
2024
Q1 | $563K | Buy |
39,009
+30,307
| +348% | +$501K | ﹤0.01% | 5106 |
|
|
2023
Q4 | $187K | Sell |
8,702
-894,570
| -99% | -$16M | ﹤0.01% | 5813 |
|
|
2023
Q3 | $17.4M | Buy |
903,272
+898,629
| +19,354% | +$19.2M | 0.01% | 1586 |
|
|
2023
Q2 | $118K | Sell |
4,643
-3,310
| -42% | -$95.6K | ﹤0.01% | 5871 |
|
|
2023
Q1 | $288K | Buy |
7,953
+6,734
| +552% | +$236K | ﹤0.01% | 5123 |
|
|
2022
Q4 | $48.3K | Buy |
1,219
+821
| +206% | +$34.1K | ﹤0.01% | 6812 |
|
|
2022
Q3 | $19K | Sell |
398
-391
| -50% | -$18.1K | ﹤0.01% | 7477 |
|
|
2022
Q2 | $35K | Buy |
789
+117
| +17% | +$6.43K | ﹤0.01% | 6231 |
|
|
2022
Q1 | $48K | Sell |
672
-31
| -4% | -$2.23K | ﹤0.01% | 6543 |
|
|
2021
Q4 | $57K | Buy |
703
+41
| +6% | +$4.11K | ﹤0.01% | 6784 |
|
|
2021
Q3 | $77K | Buy |
662
+4
| +0.6% | +$524 | ﹤0.01% | 6019 |
|
|
2021
Q2 | $109K | Sell |
658
-4,256
| -87% | -$664K | ﹤0.01% | 5815 |
|
|
2021
Q1 | $685K | Buy |
4,914
+1,130
| +30% | +$184K | ﹤0.01% | 4606 |
|
|
2020
Q4 | $655K | Buy |
3,784
+1,480
| +64% | +$240K | ﹤0.01% | 4375 |
|
|
2020
Q3 | $321K | Buy |
2,304
+1,790
| +348% | +$239K | ﹤0.01% | 4503 |
|
|
2020
Q2 | $61K | Sell |
514
-260
| -34% | -$30.8K | ﹤0.01% | 5705 |
|
|
2020
Q1 | $77K | Sell |
774
-3,914
| -83% | -$471K | ﹤0.01% | 5502 |
|
|
2019
Q4 | $551K | Sell |
4,688
-1,801
| -28% | -$178K | ﹤0.01% | 4758 |
|
|
2019
Q3 | $558K | Buy |
6,489
+56
| +0.9% | +$4.24K | ﹤0.01% | 4474 |
|
|
2019
Q2 | $417K | Sell |
6,433
-4,140
| -39% | -$258K | ﹤0.01% | 4424 |
|
|
2019
Q1 | $661K | Buy |
10,573
+6,341
| +150% | +$298K | ﹤0.01% | 3863 |
|
|
2018
Q4 | $164K | Sell |
4,232
-729
| -15% | -$32.4K | ﹤0.01% | 5116 |
|
|
2018
Q3 | $283K | Sell |
4,961
-384
| -7% | -$24K | ﹤0.01% | 4804 |
|
|
2018
Q2 | $427K | Sell |
5,345
-134
| -2% | -$11.1K | ﹤0.01% | 4438 |
|
|
2018
Q1 | $474K | Buy |
5,479
+1,509
| +38% | +$122K | ﹤0.01% | 4249 |
|
|
2017
Q4 | $274K | Sell |
3,970
-1,911
| -32% | -$153K | ﹤0.01% | 4702 |
|
|
2017
Q3 | $534K | Sell |
5,881
-33,373
| -85% | -$2.86M | ﹤0.01% | 4167 |
|
|
2017
Q2 | $2.92M | Buy |
39,254
+17,409
| +80% | +$1.39M | ﹤0.01% | 2654 |
|
|
2017
Q1 | $2.05M | Sell |
21,845
-15,111
| -41% | -$1.37M | ﹤0.01% | 2919 |
|
|
2016
Q4 | $2.69M | Buy |
36,956
+34,978
| +1,768% | +$2.99M | ﹤0.01% | 2649 |
|
|
2016
Q3 | $207K | Sell |
1,978
-193
| -9% | -$17.4K | ﹤0.01% | 4528 |
|
|
2016
Q2 | $161K | Buy |
2,171
+363
| +20% | +$24.6K | ﹤0.01% | 4689 |
|
|
2016
Q1 | $102K | Sell |
1,808
-29,482
| -94% | -$1.74M | ﹤0.01% | 4974 |
|
|
2015
Q4 | $2.11M | Buy |
31,290
+29,713
| +1,884% | +$1.59M | ﹤0.01% | 2743 |
|
|
2015
Q3 | $73K | Buy |
1,577
+340
| +27% | +$16.5K | ﹤0.01% | 5492 |
|
|
2015
Q2 | $66K | Buy |
1,237
+210
| +20% | +$10.7K | ﹤0.01% | 5757 |
|
|
2015
Q1 | $49K | Sell |
1,027
-802
| -44% | -$34.8K | ﹤0.01% | 6069 |
|
|
2014
Q4 | $71K | Buy |
+1,829
| New | +$57.6K | ﹤0.01% | 6058 |
|
Other funds holding NVRO
UBS Group's NVRO Position: Q2 2025 in Review
UBS Group sold out of NEVRO CORP. (NVRO) in Q2 2025, closing a stake of 123,082 shares — an estimated $719K sold.
UBS Group first reported a position in NVRO in Q4 2014 and held it in 42 quarters. The position peaked at $17.4M in Q3 2023. 1 fund tracked by Wall St. Rank holds NVRO as of Q2 2025.
- UBS Group reported no remaining NEVRO CORP. position as of Q2 2025 after selling out during the quarter.
- UBS Group sold 123,082 NEVRO CORP. shares in Q2 2025, an estimated $719K.
- UBS Group first reported a position in NEVRO CORP. in Q4 2014 and held it in 42 quarters.
- UBS Group's NEVRO CORP. position peaked at $17.4M in Q3 2023.
- 1 fund tracked by Wall St. Rank held NEVRO CORP. as of Q2 2025.
Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.